Alterations to genes involved in cellular metabolism and epigenetic regulation are
implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate …

Isocitrate dehydrogenases (IDHs) are enzymes involved in multiple metabolic and
epigenetic cellular processes. Mutations in IDH1 or IDH2 are detected in approximately 20 …

Purpose: Whether isocitrate dehydrogenase (IDH) gene aberrations affected prognosis of
patients with acute myeloid leukemia (AML) was controversial. Here, we conducted a meta …

Mutations of the isocitrate dehydrogenase-1 (IDH1) and IDH2 genes are among the most
frequent alterations in acute myeloid leukemia (AML) and can be found in∼ 20% of patients …

Mutations in IDH1, IDH2, and TET2 are recurrently observed in myeloid neoplasms. IDH1
and IDH2 encode isocitrate dehydrogenase isoforms, which normally catalyze the …

Background The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute
myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed …

The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is
discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 …

Mutations in IDH2 genes (m IDH2) occur in approximately 12% of patients with acute
myeloid leukemia. Enasidenib is an oral, small-molecule inhibitor of mIDH2 proteins …

Cancer cells alter their metabolism by switching from glycolysis to oxidative phosphorylation
(OXPHOS), regardless of oxygen availability. Metabolism may be a molecular target in acute …

Acute myeloid leukemia (AML) is a debilitating and life-threatening condition, especially for
elderly patients who account for over 50% of diagnoses. For over four decades, standard …